Gerstenberg, B.; Kuhn, D.; Romer, E.; Teredesai, A.; Tewes, F.; Thomas, C.
Page 7 of the document (Bates No. 2026051124) contains a glossary of abbreviations which is very helpful. This document was used as a Trial Exhibit in Minnesota's case against the industry.
This 502-page scientific report was done at INBIFO, Philip Morris's biological research lab in Europe, and was sent to Ragnar Rylander, a scientist who worked on contract for PM. It is an extensive report on mouse skin painting tests done to determine the carcinogenicity of secondhand (sidestream or "SS") smoke compared with that of mainstream ("MS") smoke. For the test, solids (or "condensate)" were derived from the particulate matter in both mainstream and sidestream smoke and painted onto the skin of 2,625 mice over an 80-week period to gauge the biological reaction.
On page 12, Bates No. 2026051129, under "Condensates," the report states that
"The concentrations of the nitrosamines NNN, NATB, NNK, NAB, NPY, and DMNA were between 0.01 and 1.9 milligrams/liter for [mainstream smoke]and between 0.08 and 6.1 milligrams/liter for [sidestream smoke]. The main differences between [mainstream] and [sidestream smoke] were the higher concentrations: of NNK, NPY, and DMNA for [sidestream]."
It also states that,
"The sum of all PAH [polycyclic aromatic hydrocarbons] were 5-fold higher for [sidestream smoke] than for [mainstream smoke]."
and, on page 14, (Bates No. 2026051131) it states that "The number of mice with signs of intoxication was higher in the [sidestream] than in [mainstream] treated groups."
It also states that:
"The comparison of the mortality of [mainstream] and [sidestream] treated mice showed a statistically significantly higher mortality in the [sidestream]treated groups. This is considered to be biologically relevant."
The "Conclusions" section on page 22 (Bates No.2026051139) states that Sidestream Whole Smoke Condensate collected with an impaction trap (SWSC-I) showed 2 to 6 times higher skin tumorigenicity than Mainstream Whole Smoke Condensate collected in the same manner (MWSC-I). Here is the quote:
"SWSC-I assayed for complete tumorigenic activity, i. e., without DMBA pretreatment, showed a 2- to 6-fold higher skin tumorigenicity than MWSC-I."
The section entitled "Mortality" on Page 14 (Bates No. 2026051131) states that,
"The comparison of the mortality of the [mainstream] and [sidestream] treated CD1 and B6C3FI mice showed a statistically significantly higher mortality in the [sidestream] treated groups. This is considered to be biological relevant."
On Page 17 (Bates No. 2026051134), a section entitled "Skin Irritations" states,
"The comparison of skin irritations in [mainstream] and [sidestream] treated CD1 mice showed a statistically significantly higher number of mice with skin irritations in the [sidestream] treated groups. This is considered to be biologically relevant."
On Page 21 (Bates No. 2026051138) a section describing "Pathological Findings" states that,
"The relative skin tumor rate (b), was statistically significantly higher in
(1) [Sidestream treated mice] without and with DMBA pretreatment than in [mainstream treated mice] without and with DMBA pretreatment...These effects are considered to be biologically relevant."
NOTE: Some of the mice were pre-treated with an "initiator" (DMBA), a chemical that was believed to help tumors start forming, but which does not to promote them once they are formed.
The report, dated 26 October 1987, seems to show that Philip Morris had done biological testing on secondhand smoke and found that secondhand smoke was more biologically active than mainstream smoke.